PROVIDING ANSWERS FOR CANCER PATIENTS

Interim report

January — June 2022

curasight

www.curasight.com

In this document, the following definitions shall apply unless otherwise specified: “the Company” or “Curasight” refers to Curasight A/S, CVR no. 35249389.

Table of contents

Key figures and selected posts

Q2 (2022-04-01 – 2022-06-30)

- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -1,919,541 (-404,869) DKK
- Profit/loss before taxes amounted to -2,876,062 (-1,079,213) DKK
- Profit/loss for the period amounted to -2,243,328 (-841,783) DKK
- Total assets amounted to 99,297,297 (60,860,495) DKK
- Equity ratio amounted to 96,3 (94,4) %.
- Earnings per share amounted to -0,11 (-0,05) DKK

H1 (2022-01-01 – 2022-06-30)

- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -2,697,418 (-771,962) DKK
- Profit/loss before taxes amounted to -4,492,362 (-2,076,728) DKK
- Profit/loss for the period amounted to -3,504,042 (-1,619,848) DKK
- Total assets amounted to 99,297,297 (60,860,495) DKK
- Equity ratio amounted to 96,3 (94,4) %.
- Earnings per share amounted to -0,17 (-0,09) DKK

Numbers in parenthesis are the numbers from the same period in 2021.

Definitions
Equity ratio: Shareholders equity as a proportion of total assets.
Earnings per share: Profit/Loss for the period divided by average number of shares.

Key figures | CEO letter | Highlights | About Curasight | Financial statements

Strong momentum and business progress made during H1

Execution on strategic objectives in first six months of the year sets up rich news flow for the second half of 2022

During the first half of 2022, we executed our expanded strategy to leverage our uPAR theranostics platform, a two-pronged approach to provide more accurate diagnosis via intelligent cancer imaging (uTRACE®) and more focused and efficient treatment options (uTREAT®), to deliver on our mission of improving the lives of millions of people suffering from certain types of cancer.

One of the major highlights this quarter was the completion of recruitment in the investigator-initiated phase II study of uTRACE® in brain cancer performed by researchers at the renowned teaching hospital in Copenhagen, Rigshospitalet. We are extremely pleased that all patients are now enrolled in this trial, despite the early challenges caused by the COVID-19 pandemic. The phase II trial is designed to investigate the diagnostic performance of uPAR-PET in brain cancer and we very much look forward to the reporting of data from this study during the second half of the year. We also aim to gain important insights from this uTRACE® study that will help inform us on how best to develop our uPAR-targeting radionuclide therapy uTREAT® in brain cancer patients, in particular the most aggressive high-grade gliomas. We look forward to giving more details on our integrated strategy for further development of both uTRACE® and uTREAT® in brain cancer, in the coming months.

A total of approx. 65,000 patients are diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed with the aggressive form, Glioblastoma, annually in the US and EU. Glioblastoma currently has a very poor prognosis with a median survival of only 14 months and five-year survival of only 5%. Despite intensive treatment efforts, including surgical resection, external radiation therapy, and chemotherapy. Therefore, we are confident that our combined diagnostic and therapeutic, so-called theranostic solution may significantly improve the treatment and thus the survival rate of these patients where little improvement in the treatment has been seen over the last decade. This technology, together with a strong and broad pipeline of studies, puts Curasight in a good position in a globally growing market to generate long-term value for its shareholders.

An important value driver for Curasight is also that we ensure we have robust patent protection for our technologies. We were therefore very pleased that in April we could add one more U.S. granted patent to our family of patents. The United States Patent and Trademark Office granted our patent application relating to Curasight's diagnostic technology uTRACE® (64Cu-imaging agent) and together with the already issued patent for uTRACE® based on the 68Ga-imaging agent, the uTRACE® platform now consists of two imaging agents targeting uPAR but with different characteristics. The grant is essential to our commercial strategy as we develop uTRACE® into a comprehensive diagnostic platform.

After a busy first half of the year, we look forward to making further progress during the next six months as we continue to execute our strategy. As mentioned earlier, we eagerly await the results from the investigator-initiated phase II study (uTRACE®) in brain cancer. We also anticipate announcing preclinical data from using our uTRACE® technology in brain cancer. Additionally, we aim to initiate pre-clinical studies of the therapeutic compound (uTREAT®) in neuroendocrine tumours and head and neck cancer and to further communicate our strategy for both uTRACE® and uTREAT® in brain cancer.

Together with a strong financial position of DKK 60 million expected to last well into 2023 and an expanded strategy adding two additional indications to uTRACE®, I am confident that the next two quarters will continue to build our business by progressing the pipeline.

Ulrich Krasilnikoff, CEO
Curasight A/S

"With all patients now recruited in the investigator-initiated phase II study (uTRACE®) in brain cancer, we eagerly await the results as we accelerate the development of the theranostic solution – combining diagnostics with therapy."

Highlights

During the second quarter 2022

On April 22, Curasight announced that the United States Patent and Trademark Office has granted Curasight's United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137.

On April 25, Ulrich Krasilnikoff and Andreas Kjær were invited and attended Sedermeradagen Stockholm. The presentation is available on Sedermeras Youtube channel.

On April 27, Curasight held an Annual General Meeting. Resolutions with summarized decisions are available on the company's website.

On May 18, Ulrich Krasilnikoff and Andreas Kjær gave an update on the company's strategy at Kapital Partner's Life Science Seminar.

On June 7, Curasight issued a total of 956,770 warrants for the purpose of launching the Company's long-term incentive program covering the Company's Board of Directors, Executive Management and other key employees.

On June 24, Curasight announced that a transaction with shares in Curasight A/S was made by managerial employee in the period 9 – 10 June 2022. Hanne Damgaard Jensen (Chief Development Officer) bought a total of 16.400 shares. Hanne Damgaard Jensen total holdings in Curasight A/S after the purchase of the shares is 20,000 shares.

On June 30, Curasight announced that the investigator-initiated phase II study using uPAR-PET in brain cancer had completed the inclusion of patients. First data from the study is expected to be published during H2 2022.

Analyses

S|E|B

SEB initiated its commissioned research on June 18, 2021, and has since then continuously monitored and analyzed Curasight's operations, products, markets, and competitors.

SEB's corporate page on Curasight is available at the following link:
https://research.sebgroup.com/corporate/companies/2853/overview

KAPITAL | PARTNER

KapitalPartner initiated its commissioned research on August 2021, and has since then continuously monitored and analyzed Curasight's operations, products, markets, and competitors.

KapitalPartner's corporate page on Curasight is available at the following link:
https://kapitalpartner.dk/curasight/

Curasight A/S in short

Curasight is a clinical phase II company based in Copenhagen, Denmark. Curasight's team are the pioneers behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy with the precise uTRACE® diagnostics. Several investigator-initiated phase II clinical trials have been completed or are currently undertaken.

PET-imaging, usually combined with CT as PET/ CT, is used to create images in which the biology of the disease can be studied. The principle is that a radiolabelled tracer is injected and bound to the tissues, e.g. in a tumor, after which the radioactivity can be located with the help of a PET-scanner. Together with his team, Professor Andreas Kjaer, developed a platform based on the radiolabelled PET-tracer uTRACE®, Curasight's novel product that highlights the cancer biomarker uPAR. By injecting the patient with uTRACE®, one can both image where the cancer is located and its level of aggressiveness.

uTRACE® is imaging invasion and formation of cancer metastases (breaking down the normal tissue around the tumour). By imaging this, Curasight's technology can diagnose and determine which therapeutic strategy should be pursued, e.g. if the patient needs surgery or not. In addition, uTRACE® will be used for theranostics (principle of combined therapy and diagnostics) and precision medicine, selecting the right therapy to the right person at the right time, creating substantial benefits for both patients and the healthcare system.

Curasight's solution is expected to have big advantages in the future evaluation of prostate cancer because it may determine whether surgery is necessary or not. Today most prostate cancer patients having prostatectomies performed are operated unnecessarily and most of these patients (up to 70 percent) experience some degree of side effects, such as impotence. With Curasight's product and diagnosis, it is the company's assessment that the degree of uncertainty will be dramaticallly reduced, and these patients can be managed according to their needs – with the necessary treatment at the right time, improving patient management and generating substantial business potential.

Curasight's technology has been and is currently tested in a broad pipeline of 5 completed and 3 ongoing phase II clinical trials. According to the board's assessments, there is currently no other early-stage biotech company in the field of PET tracer development that has their technology tested in a broader portfolio of clinical trials in humans (Investigator-initiated and academically sponsored), in many different cancer indications. In 2017 a phase I/IIa first-in-humans clinical trial with uTRACE® was completed. In 2018 a phase IIb clinical trial with uTRACE® in breast cancer was completed, in 2020 a phase II study in prostate cancer and in 2021/2022 two studies in head-and-neck cancer and neuroendocrine tumors.

Moving into targeted radionuclide therapy (theranostics) – the radiation therapy of the future. With the promising results obtained within diagnostics Curasight now also pursues uPAR targeted radionuclide therapy using the uTRACE® ligand but "armed" with short-range (1 mm) radiation therapy. In brief, the therapeutic ligand will be injected into a vein after which it will circulate and bind to all cancer cells in the body (expressing uPAR) and locally irradiate cancer with limited irradiation of healthy tissue. This concept represents a gentler form of radiotherapy compared to



traditional external radiation therapy and is therefore by many is considered the "radiation therapy of tomorrow". As PET imaging and radionuclide therapy are based on the same uPAR binding peptide, a uTRACE®-scan can precisely predict where subsequent targeted radiation therapy will be delivered (theranostic principle).

Business model

Curasight aims to establish uTRACE® as an alternative to biopsies for risk stratification in prostate cancer. The geographic markets with the highest prevalence of these cancers are the U.S. and Europe. The Board and management of Curasight assess that the market potential for uTRACE® as an integral component of a new and fast-growing market for active surveillance is substantial. Importantly, as a result of the unique patient benefits and its compelling business model, Curasight expects uTRACE® to catalyse the market for active surveillance. In brain cancer, Curasight expects its Theranostic solution uTREAT® to be game-changing and to obtain a substantial market share. The orphan (rare) disease status of this disease is expected to enable a "fast track" route to FDA approval. By establishing an advanced pipeline in multiple cancer indications, Curasight's board and management believe the Company will be an attractive candidate for partnership or out licensing agreement with Big Pharma. The area within Nuclear Molecular Imaging/Therapy has experienced strong traction with significant exit benchmarks over the recent period.

Outlook for Curasight

Curasight's first goal is to advance its lead products uTREAT® (used for therapy) and uTRACE® (used for diagnosing) to improve outcomes for the approx. 65,000 patients in the US and EU that are diagnosed annually with brain tumours. Accordingly, approximately 30,000 patients are diagnosed with high-grade glioma where the prognosis is very poor. Glioblastoma is a rare disease in both markets, qualifying for drug Orphan Drug Designation; moreover, because of the high unmet need, products targeting it are more likely to qualify for e.g. Priority Review, Breakthrough Therapy Designation, or Accelerated Approval.

Besides, due to the very encouraging results from the finalised clinical phase-II study in Prostate Cancer, Curasight will look into how to accelerate the product development of uTRACE®, a more flexible and non-invasive risk stratification tool compared to the present gold standard, for the prostate cancer patients entering or being followed in active surveillance programs.

Furthermore, Curasight is looking into how to unfold further our platform and how to broaden the mission to realize the vast potential of uTRACE® for diagnosing and uTREAT® for targeted radionuclide therapy in other cancer types where uPAR is also expressed.

With reference to the recently published positive results from the investigator-initiated phase II studies performed by researchers at Rigshospitalet, using the uTRACE® technology in both Neuroendocrine tumors (NET) and head and neck cancer, Curasight has decided also to further develop uTRACE® for use in these two indications in order to obtain FDA approval.

This will be added to the existing program with uTRACE® in brain cancer, which is still the lead indication both within diagnostics and therapy, in addition to prostate cancer. The expectation is still to get uTRACE® approved for use in brain cancer. Going forward, Curasight's clinical development in diagnostics, uTRACE®, will thus include two additional phase III studies, comprising neuroendocrine tumors (NET) besides head and neck cancer, which strengthens the strategic position with uTRACE® as a diagnostic platform and increases the commercial opportunities considerably.

Similarly, Curasight will also, in addition to brain cancer, develop a therapeutic option with uTREAT® for neuroendocrine tumors (NET) as well as for head and neck cancer.

About neuroendocrine tumors

Each year approximately 35,000 new cases are diagnosed in the US and EU. Due to the long survival of these patients, more than 400,000 patients are living with the disease in the US and EU. Neuroendocrine tumors are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body.

About head and neck cancer

Head and neck squamous cell carcinoma is the 6th most common cancer worldwide with 890,000 new cases and 450,000 deaths in 2018. The incidence is anticipated to increase over the coming years.

Strategic Partnerships in Theranostics

To support and accelerate the strategic business development, discussions are currently underway with a number of major pharma companies with a view to uncovering opportunities and interest within the individual cancer indications. The discussions aim at both co-financing the crucial phase III studies with uTRACE®, as well as the subsequent go-to market strategy. This also Includes participation in the final development of uTREAT® within treatment in the same indications.

Key milestones 2022

(i)	**H1 2022:** Inclusion completed in the investigator-initiated phase IIb clinical study in brain cancer with uTRACE®.
(ii)	**H1 2022:** Results from investigator-initiated phase IIb clinical study in head and neck cancer with uTRACE®, (study published).
(iii)	**H1 2022:** Results from investigator-initiated phase IIb clinical study in neuroendocrine tumours (NET) with uTRACE®, (study published).
(iv)	**Q1 2022:** Presentation of extended strategy comprising accelerated clinical program with uTRACE® and uTREAT®.
(v)	**H2 2022:** Results from pre-clinical study in brain cancer with uTREAT®.
(vi)	**H2 2022:** Initiation of pre-clinical studies with uTREAT® in head and neck cancer.
(vii)	**H2 2022:** Initiation of pre-clinical studies with uTREAT® in neuroendocrine tumours (NET).
(viii)	**Q4 2022:** Scientific advice meeting with FDA on uTRACE® in prostate cancer.

Investigational Candidates in Clinical Development

Sponsor: the National University Hospital of Denmark (Rigshospitalet)

- uTRACE© Diagnostic platform
- uTREAT© Therapeutic platform
- Planned studies
- Completed investigator-initiated studies

Miscellaneous

Shareholders

The table below presents the management's shareholdings in Curasight.

Name	Votes & capital (%)
AK 2014 Holding ApS[1]	30.24
UK Curacap ApS[2]	20.01
CHN Holding ApS[3]	12.11
Madsen Holding 2013 ApS[4]	4.57
LT 2003 ApS[5]	2.95
Per Falholt[6]	0.33
Charlotte Vedel[7]	0.20
Kirsten Drejer[8]	0.02
Hanne Damgaard jensen[9]	0.01

1. Owned by co-founder, CSO, and Board Member Andreas Kjaer
2. Owned by CEO and Board Member Ulrich Krasilnikoff
3. Owned by co-founder and Director Pre-Clinical Carsten H Nielsen
4. Owned by Co-founder and Director CMC, Jacob Madsen
5. Owned by Deputy Chairman of the Board, Lars Trolle
6. Chairman of the Board
7. Board Member
8. Board Member
9. Chief Development Officer (CDO)

The share

The shares of Curasight A/S were listed on Spotlight Stock Market on October 8, 2020.

The short name/ticker is CURAS, and the ISIN code is DK0061295797. As of June 30, 2022, the number of shares was 19,893,891 (17,126,340). All shares have equal rights to the Company´s assets and results.

Long-term incentive program

Curasight has a long-term incentive program covering the financial years 2022-2025 with a total of 956,770 warrants covering the Company's Board of Directors, Executive Management and other key employees. For the Board of Directors, a total of 229,230 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 11,461.50 nominally worth of shares in the Company. The warrants are allocated between Per Falholt (chairman of the Board of Directors), Lars Trolle (vice-chairman of the Board of Directors), Charlotte Vedel (member of the Board of Directors) and Kirsten Aarup Drejer (member of the Board of Directors).

For the Executive Management and other key employees of the Company, a total of 727,540 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 36,377.00 nominally worth of shares in the Company. The warrants are allocated between Ulrich Krasilnikoff (CEO), Andreas Kjær (CSO), Hanne Damgaard Jensen (CDO), Nic Gillings (Head of Quality Assurance and Regulatory Affairs) and Jacob Madsen (Director CMC).

Risks

A number of risk factors can affect Curasight's operations. It is therefore of great importance to consider relevant risks in addition to the Company's growth opportunities. For a detailed description of the risks attributable to the Company and its shares, please refer to the prospectus published by the Company in 2020. The prospectus is available on Curasight's website www.curasight.com.

Accounting policy

The financial statements have been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B as well as selected rules applying to reporting class C. This interim report has been prepared using the same accounting principles.

Auditor´s review

The interim report has not been reviewed by the Company's auditor.

Financial calendar	
Q3 2022	November 24, 2022
Year-end report Q4 2022	February 23, 2023
AGM 2023	March 30, 2023

For further information, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com

Financial statements

Income statement
Operating profit/loss before tax for the second quarter of 2022 amounted to DKK -2,876,062 (-1,079,213). Operating profit/loss before tax for the first half of 2022 amounted to DKK -4,492,362 (-2,076,728).

External expenses for the second quarter amounted to DKK -2,706,064 (-1,010,043) and staff expenses are DKK -539,109 (-357,760). External expenses for the first half of 2022 amounted to DKK -4,136,190 (-1,941,281) and staff expenses are DKK -943,944 (-653,503). External expenses comprise of clinical expenses, patent expenses, and business expenses.

Balance sheet
Per June 30, 2022, the Company's balance sheet amounted to DKK 99,297,297 (60,860,495). The assets consisted primarily of development projects totalling DKK 27,544,029 related to the development of uTRACE® and uTREAT®. The Company's cash amounted to DKK 60,046,256. The equity and liabilities consisted primarily of an equity totalling DKK 95,649,648.

Cash flow
Curasight's cash flow from operating activities in January–June 2022 amounted to DKK -1,730,850. This post was primarily affected by the Company's loss for the period of DKK -2,243,328.

Cash as of June 30, 2022, was DKK 60,046,256 (34,092,041).

Income statement

(DKK)	2022 Q2*	2021 Q2*	2022 Q1-Q2*	2021 Q1-Q2*	2021 Q1-Q4
Gross profit/loss	**-1,919,541**	**-404,869**	**-2,697,418**	**-771,962**	**-6,210,420**
Staff expenses	-539,109	-357,760	-943,944	-653,503	-1,151,551
Depreciation, amortisation and impairment of intangible assets and property, plant and equipment	-247,414	-247,414	-494,828	-515,816	-1,010,644
Profit/loss before financial income and expenses	**-2,706,064**	**-1,010,043**	**-4,136,190**	**-1,941,281**	**-8,372,615**
Financial costs	-169,998	-69,170	-356,172	-135,447	-379,900
Profit/loss before tax	**-2,876,062**	**-1,079,213**	**-4,492,362**	**-2,076,728**	**-8,752,515**
Tax on profit/loss for the period	632,734	237,430	988,320	456,880	1,173,845
Net profit/loss for the period	**-2,243,328**	**-841,783**	**-3,504,042**	**-1,619,848**	**-7,578,670**

*) Unaudited figures

Balance sheet - Assets

(DKK)	2022 Q1-Q2*	2021 Q1-Q2*	2021 Q1-Q4
Acquired patents	2,021,649	2,971,573	2,496,611
Development projects in progress	27,544,029	22,467,573	24,698,847
Intangible assets	**29,565,678**	**25,439,146**	**27,195,458**
Other fixtures and fittings, tools and equipment	158,952	198,684	178,818
Property, plant and equipment	**158,952**	**198,684**	**178,818**
Acquired shares in subsidary	7,422,680	0	0
Financial fixed assets	**7,422,680**	**0**	**0**
Fixed assets	**37,147,310**	**25,637,830**	**27,374,276**
Other receivables	1,115,411	256,840	592,504
Corporation tax	988,320	873,784	1,083,344
Receivables	**2,103,731**	**1,130,624**	**1,675,848**
Cash at bank and in hand	**60,046,256**	**34,092,041**	**73,564,174**
Currents assets	**62,149,987**	**35,222,665**	**75,240,022**
Assets	**99,297,297**	**60,860,495**	**102,614,298**

*) Unaudited figures

Balance sheet - Liabilities and equity

(DKK)	2022 Q1-Q2*	2021 Q1-Q2*	2021 Q1-Q4
Share capital	994,695	856,317	994,695
Reserve for development costs	23,311,457	19,429,935	21,212,458
Retained earnings	71,343,496	37,224,382	76,946,537
Equity	**95,649,648**	**57,510,634**	**99,153,690**
Provision for deferred tax	715,576	1,953,587	1,446,182
Provisions	**715,576**	**1,953,587**	**1,446,182**
Trade payables	1,625,845	1,895	704,865
Deferred income	1,128,108	1,082,417	1,128,109
Other payables	178,120	311,962	181,452
Short-term debt	**2,932,073**	**1,396,274**	**2,014,426**
Debt	**2,932,073**	**1,396,274**	**2,014,426**
Liabilities and equity	**99,297,297**	**60,860,495**	**102,614,298**

*) Unaudited figures

Equity - Q2 2022

(DKK) Change in Equity: Q2-2022*	Share capital	Reserve for development costs	Retained earnings	Total
Equity at 1 April 2022	**994,695**	**21,827,458**	**75,070,823**	**97,892,976**
Development costs for the period	0	1,483,999	-1,483,999	0
Net profit/loss for the period	0	0	-2,243,328	-2,243,328
Equity at 30 June 2022	**994,695**	**23,311,457**	**71,343,496**	**95,649,648**

Equity - Q2 2021

(DKK) Change in Equity: Q2-2021*	Share capital	Reserve for development costs	Retained earnings	Total
Equity at 1 April 2021	**856,317**	**19,030,935**	**38,465,165**	**58,352,417**
Development costs for the period	0	399,000	-399,000	0
Net profit/loss for the period	0	0	-841,783	-841,783
Equity at 30 June 2021	**856,317**	**19,429,935**	**37,224,382**	**57,510,634**

Equity - H1 2022

(DKK) Change in Equity: Q1-Q2 2022*	Share capital	Reserve for development costs	Retained earnings	Total
Equity at 1 January 2022	**994,695**	**21,212,458**	**76,946,537**	**99,153,690**
Development costs for the period	0	2,098,999	-2,098,999	0
Net profit/loss for the period	0	0	-3,504,042	-3,504,042
Equity at 30 June 2022	**994,695**	**23,311,457**	**71,343,496**	**95,649,648**

*) Unaudited figures

Equity - H1 2021

(DKK) Change in Equity: Q1-Q2 2021*	Share capital	Reserve for development costs	Retained earnings	Total
Equity at 1 January 2021	**856,317**	**18,631,935**	**39,642,230**	**59,130,482**
Development costs for the period	0	798,000	-798,000	0
Net profit/loss for the period	0	0	-1,619,848	-1,619,848
Equity at 30 June 2021	**856,317**	**19,429,935**	**37,224,382**	**57,510,634**

Equity - FY 2021

(DKK) Change in Equity: Q1-Q4 2021	Share capital	Share Premium Account	Reserve for development costs	Retained earnings	Total
Equity at 1 January 2021	**856,317**	**0**	**18,631,935**	**39,642,230**	**59,130,482**
Cash capital increase	138,378	47,463,500	0	0	47,601,878
Development costs for the period	0	0	2,580,523	-2,580,523	0
Net profit/loss for the period	0	0	0	-7,578,670	-7,578,670
Transfer from share premium account	0	-47,463,500	0	47,463,500	0
Equity at 31 December 2021	**994,695**	**0**	**21,212,458**	**76,946,537**	**99,153,690**

*) Unaudited figures

Cash flow statement

(DKK)	2022 Q2*	2021 Q2*	2022 Q1-Q2*	2021 Q1-Q2*	2021 Q1-Q4
Net profit/loss for the year	-2,243,328	-841,783	-3,504,042	-1,619,848	-7,578,670
Adjustments	247,414	-56,293	494,828	58,936	216,699
Change in working capital	265,064	-165,270	-237,409	366,033	513,074
Cash flow from operating activities before financial income and expenses	**-1,730,850**	**-1,063,346**	**-3,246,623**	**-1,194,879**	**-6,848,897**
Financial expenses	-169,998	-69,170	-356,172	-135,447	-379,898
Cash flow from ordinary activities	**-1,900,848**	**-1,132,516**	**-3,602,795**	**-1,330,326**	**-7,228,795**
Corporation tax received/payed	0	0	352,739	-63,885	-63,886
Cash flows from operating activities	**-1,900,848**	**-1,132,516**	**-3,250,056**	**-1,394,211**	**-7,292,681**
Purchase of intangible assets	-1,483,999	-399,000	-10,267,862	-798,000	-3,029,275
Cash flow from investing activities	**-1,483,999**	**-399,000**	**-10,267,862**	**-798,000**	**-3,029,275**
Cash capital increase	0	0	0	0	47,601,878
Cash captial reduction	0	0	0	0	0
Other equity entries	0	0	0	0	0
Cash flow from financing activities	**0**	**0**	**0**	**0**	**47,601,878**
Change in cash and cash equivalents	**-3,384,847**	**-1,531,516**	**-13,517,918**	**-2,192,211**	**37,279,922**
Cash and cash equivalents the beginning of period	63,431,103	35,623,557	73,564,174	36,284,252	36,284,252
Cash and cash equivalents at end of period	**60,046,256**	**34,092,041**	**60,046,256**	**34,092,041**	**73,564,174**
Cash and cash equivalents are specified as follows: Cash at bank and in hand	60,046,256	34,092,041	60,046,256	34,092,041	73,564,174
Cash and cash equivalents at end of period	**60,046,256**	**34,092,041**	**60,046,256**	**34,092,041**	**73,564,174**

*) Unaudited figures

Statement by the Board of Directors

The Board of Directors provide their assurance that the Interim report provides a fair and true overview of the Company's operations, financial position, and results.

København N, August 25, 2022

Executive Board
Ulrich Krasilnikoff, CEO

Board of Directors
Per Falholt, Chairman
Lars Trolle
Kirsten Drejer
Charlotte Vedel
Ulrich Krasilnikoff
Andreas Kjær

Contact information
Curasight A/S
Ole Maaløes Vej 3
2200 Copenhagen
Denmark
Email: info@curasight.com
Phone: +4522830160

Curasight

Curasight's team are the pioneers behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy, with the precise uTRACE® diagnostics. Several investigator-initiated phase II clinical trials have been completed or are currently undertaken.

curasight

www.curasight.com